Affordable Medicines Utilization Act of 2011 encourages use of generic drugs
WASHINGTON — New bipartisan legislation introduced to the Senate last week seeks to offer states incentives to use generic drugs by allowing states to temporarily keep a portion of the savings.
Senators Scott Brown, R-Mass.; Ron Wyden, D-Ore.; and John McCain, R-Ariz., introduced the Affordable Medicines Utilization Act of 2011, saying that the bill would encourage states to take advantage of cost-saving generic drugs.
“With our nation in a financial crisis and as federal and state healthcare expenditures continue to rise, we must ensure that our healthcare programs are efficiently managed,” McCain said. “A recent study found that the federal/state Medicaid program potentially overspends by more than $300 million per year on brand-name drugs when a cheaper generic drug equivalent is available. This bipartisan proposal incentivizes state Medicaid programs to substitute generics for more expensive brand-name drugs, introducing real competition for reimbursement dollars and saving taxpayers’ hard-earned money.”
The bipartisan legislation has received endorsement from the National Association of Chain Drug Stores, stating in a letter that, “The Affordable Medicines Utilization Act of 2011 will provide incentives that will encourage state programs to efficiently use their healthcare dollars through increased use of more cost-efficient generic drugs while at the same time generating savings for not only the state but for the patient as well,” NACDS wrote.
NACDS did, however, caution against "evaluating spending on prescription drugs in a vacuum."
Investigational antidepressant garners positive results in late-stage clinical trial
NEW YORK — Patients taking an investigative antidepressant undergoing late-stage clinical development showed “significant” improvement, according to study results released Monday.
Forest Labs and Pierre Fabre Medicament announced results of a phase-3 trial of levomilnacipran in adults with major depressive disorder. Results showed a statistically significant improvement in patients treated with the drug, compared with those taking placebo.
“Depressed patients often struggle to find the right antidepressant, and the need for new medications is high,” Forest Research Institute SVP research and development Marco Taglietti said. “These positive phase-3 results are very encouraging and support the continued research of levomilnacipran in adult patients with major depressive disorder.”
Ranbaxy to produce, market antiretrovirals under licensing agreement with Gilead
GURGAON, India — Ranbaxy will produce and market three HIV/AIDS drugs that currently are in late-stage clinical development by Gilead under a new licensing agreement between the drug makers.
Under the agreement, Ranbaxy said it would produce and market the following drugs in India and other developing nations after gaining necessary regulatory approval: elvitegravir, an investigational integrase inhibitor; cobicistat, an investigational antiretroviral boosting agent; and the “Quad,” a once-daily, single-tablet combination of four separate Gilead medicines. Ranbaxy and Gilead first teamed up in 2006 to market tenofovir and emtricitabine in India and many other developing nations.
“We appreciate Gilead’s initiatives for the treatment of HIV/AIDS in the developing world, through partnerships," Ranbaxy’s global pharmaceutical business president Rajiv Gulati said. "We are pleased to extend our partnership with Gilead for the in-licensed new antiretrovirals that will enhance our capability to provide quality affordable medicines for the treatment of HIV/AIDS in the developing countries.”